Thus, we speculated that CTLA-4 expressed by either ESCC tumor cells or infiltrating lymphocytes contributes to the profile of immunosuppression that is observed in ESCC patients based on its ability to impair the function and survival of activated tumor-specific T cells. Here, CTLA4 is linked to neoplasm.